Logo image of IMNM

IMMUNOME INC (IMNM) Stock Fundamental Analysis

USA - NASDAQ:IMNM - US45257U1088 - Common Stock

16.6 USD
+0.91 (+5.8%)
Last: 10/27/2025, 8:00:02 PM
16.93 USD
+0.33 (+1.99%)
After Hours: 10/27/2025, 8:00:02 PM
Fundamental Rating

3

IMNM gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for IMNM as it has an excellent financial health rating, but there are worries on the profitability. IMNM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

IMNM had negative earnings in the past year.
In the past year IMNM has reported a negative cash flow from operations.
IMNM had negative earnings in each of the past 5 years.
In the past 5 years IMNM always reported negative operating cash flow.
IMNM Yearly Net Income VS EBIT VS OCF VS FCFIMNM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

IMNM has a Return On Assets of -71.68%. This is in the lower half of the industry: IMNM underperforms 62.73% of its industry peers.
IMNM has a Return On Equity of -78.87%. This is comparable to the rest of the industry: IMNM outperforms 53.37% of its industry peers.
Industry RankSector Rank
ROA -71.68%
ROE -78.87%
ROIC N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
IMNM Yearly ROA, ROE, ROICIMNM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

IMNM does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMNM Yearly Profit, Operating, Gross MarginsIMNM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

8

2. Health

2.1 Basic Checks

IMNM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IMNM has been increased compared to 1 year ago.
The number of shares outstanding for IMNM has been increased compared to 5 years ago.
IMNM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMNM Yearly Shares OutstandingIMNM Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
IMNM Yearly Total Debt VS Total AssetsIMNM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 26.44 indicates that IMNM is not in any danger for bankruptcy at the moment.
IMNM has a better Altman-Z score (26.44) than 92.32% of its industry peers.
There is no outstanding debt for IMNM. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.44
ROIC/WACCN/A
WACC8.66%
IMNM Yearly LT Debt VS Equity VS FCFIMNM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

IMNM has a Current Ratio of 12.13. This indicates that IMNM is financially healthy and has no problem in meeting its short term obligations.
IMNM has a Current ratio of 12.13. This is amongst the best in the industry. IMNM outperforms 85.21% of its industry peers.
A Quick Ratio of 12.13 indicates that IMNM has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 12.13, IMNM belongs to the top of the industry, outperforming 85.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.13
Quick Ratio 12.13
IMNM Yearly Current Assets VS Current LiabilitesIMNM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

IMNM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.34%, which is quite impressive.
Looking at the last year, IMNM shows a quite strong growth in Revenue. The Revenue has grown by 16.68% in the last year.
EPS 1Y (TTM)45.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)16.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%69.84%

3.2 Future

IMNM is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.97% yearly.
The Revenue is expected to grow by 95.79% on average over the next years. This is a very strong growth
EPS Next Y57.75%
EPS Next 2Y23.51%
EPS Next 3Y16.29%
EPS Next 5Y14.97%
Revenue Next Year-19.9%
Revenue Next 2Y21.95%
Revenue Next 3Y101.99%
Revenue Next 5Y95.79%

3.3 Evolution

IMNM Yearly Revenue VS EstimatesIMNM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
IMNM Yearly EPS VS EstimatesIMNM Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

IMNM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year IMNM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMNM Price Earnings VS Forward Price EarningsIMNM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMNM Per share dataIMNM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as IMNM's earnings are expected to grow with 16.29% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.51%
EPS Next 3Y16.29%

More info and screens

0

5. Dividend

5.1 Amount

IMNM does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNOME INC

NASDAQ:IMNM (10/27/2025, 8:00:02 PM)

After market: 16.93 +0.33 (+1.99%)

16.6

+0.91 (+5.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-17 2025-11-17/amc
Inst Owners87.05%
Inst Owner Change0.22%
Ins Owners1.71%
Ins Owner Change0.72%
Market Cap1.45B
Revenue(TTM)12.59M
Net Income(TTM)-212386000
Analysts85.56
Price Target24.68 (48.67%)
Short Float %19.44%
Short Ratio11.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.23%
Min EPS beat(2)7.32%
Max EPS beat(2)25.15%
EPS beat(4)2
Avg EPS beat(4)-30.32%
Min EPS beat(4)-116.8%
Max EPS beat(4)25.15%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)677.56%
Min Revenue beat(2)451.08%
Max Revenue beat(2)904.04%
Revenue beat(4)3
Avg Revenue beat(4)343.48%
Min Revenue beat(4)-14.94%
Max Revenue beat(4)904.04%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.83%
PT rev (3m)-1.22%
EPS NQ rev (1m)1.01%
EPS NQ rev (3m)-2.73%
EPS NY rev (1m)0.05%
EPS NY rev (3m)3.22%
Revenue NQ rev (1m)580%
Revenue NQ rev (3m)18.64%
Revenue NY rev (1m)8.85%
Revenue NY rev (3m)56.77%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 114.79
P/FCF N/A
P/OCF N/A
P/B 5.37
P/tB 5.37
EV/EBITDA N/A
EPS(TTM)-3.08
EYN/A
EPS(NY)-2.45
Fwd EYN/A
FCF(TTM)-2.26
FCFYN/A
OCF(TTM)-2.05
OCFYN/A
SpS0.14
BVpS3.09
TBVpS3.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71.68%
ROE -78.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-116.62%
ROA(5y)-86.52%
ROE(3y)-158.72%
ROE(5y)-114.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 636.63%
Cap/Sales 143.72%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.13
Quick Ratio 12.13
Altman-Z 26.44
F-Score6
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)906.42%
Cap/Depr(5y)561.48%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y57.75%
EPS Next 2Y23.51%
EPS Next 3Y16.29%
EPS Next 5Y14.97%
Revenue 1Y (TTM)16.68%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%69.84%
Revenue Next Year-19.9%
Revenue Next 2Y21.95%
Revenue Next 3Y101.99%
Revenue Next 5Y95.79%
EBIT growth 1Y-162.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5361.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4294.44%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOME INC / IMNM FAQ

What is the ChartMill fundamental rating of IMMUNOME INC (IMNM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to IMNM.


Can you provide the valuation status for IMMUNOME INC?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNOME INC (IMNM). This can be considered as Overvalued.


What is the profitability of IMNM stock?

IMMUNOME INC (IMNM) has a profitability rating of 0 / 10.


What is the earnings growth outlook for IMMUNOME INC?

The Earnings per Share (EPS) of IMMUNOME INC (IMNM) is expected to grow by 57.75% in the next year.